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Stratification of ovarian tumor pathology
by expression of programmed cell death-1
(PD-1) and PD-ligand- 1 (PD-L1) in ovarian
cancer
Maureen L. Drakes1*, Swati Mehrotra2, Monica Aldulescu2, Ronald K. Potkul3, Yueying Liu4, Anne Grisoli4,
Cara Joyce5, Timothy E. O’Brien6, M. Sharon Stack4 and Patrick J. Stiff1
Abstract
Background: Ovarian cancer is the major cause of death among gynecologic cancers with 75% of patients
diagnosed with advanced disease, and only 20% of these patients having a survival duration of five years.
Treatments blocking immune checkpoint molecules, programmed cell death (PD-1) or its ligand PD-ligand- I (PD-
L1) have produced a beneficial and prolonged effect in a subgroup of these patients. However, there is debate in
the literature concerning the prognostic value of the expression of these molecules in tumors, with immunotherapy
responsiveness, and survival.
We evaluated the immune landscape of the ovarian tumor microenvironment of patients, by measuring the impact
of the expression of tumor PD-1, PD-L1 and infiltrating lymphocytes on stage and grade of tumors and survival, in a
cohort of 55 patients with gynecologic malignancies. Most patients under study were diagnosed with advanced
disease ovarian cancer.
Results: Our studies revealed that a low density of PD-1 and of PD-L1 expressing cells in tumor tissue were
significantly associated with advanced disease (P = 0.028 and P = 0.033, respectively). Moreover, PD-L1 was expressed
significantly more often in high grade tumors (41.5%) than in low grade tumors of patients (7.7%) (P = 0.040). The
presence of CD3 or of FoxP3 infiltrating cells with PD-L1 in patient tumors did not impact the significance of the
association of PD-L1 with high grade tumors (P = 0.040), and our analyses did not show an association between the
presence of PD-1 or PD-L1 and survival.
Conclusions: We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors,
expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling.
Keywords: Programmed cell death-1, Programmed cell death-1 ligand, High grade disease, Cancer immunotherapy,
Ovarian cancer
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Background
The early signs of ovarian cancer are asymptomatic and
thus approximately 75 % of cases are detected in the ad-
vanced metastatic stages. Conventional management strat-
egies for advanced disease include cytoreductive surgery
and chemotherapy. Most current treatments are not cura-
tive for patients with advanced disease and hence survival
for this category of patients is low [1]. It is estimated that
in 2017 there will be 22,440 new cases of ovarian cancer
in the Unites States, and that 14,080 patients will die due
to this disease [2]. Approximately 80 % of patients diag-
nosed with late stage ovarian cancer die within five years.
To provide more effective treatment options for patients,
several clinical trials are ongoing using novel single and
combination regimens to improve survival. For cancer ther-
apy, there have been several distinct landmarks in the de-
velopment of new therapies and FDA approved treatments
over the last decade [3]. However, even with the current
treatment options a considerable number of patients are
not yet receiving adequate therapy for the management of
advanced stage ovarian cancer and other malignancies.
The development and optimization of the use of novel
therapies such as immunotherapy, requires an in-depth un-
derstanding of specific target molecules and cellular inter-
actions in tumors. Early efforts in immunotherapy can be
traced to 1891, in which administration of intra-tumoral in-
jections of bacteria led to a shrinkage of patients’ tumor [4,
5]. Since then, significant progress has been made in the
field [6]. One of the recent highlights in novel treatment
options for cancer has been the targeting of immune check-
point inhibitory molecules [7–9]. Immune checkpoints are
critically important in health and disease. They represent
co-signaling pathways which are either costimulatory or
coinhibitory. In the body, linkage of coinhibitory receptor
and ligand suppresses T cell receptor signaling, and limits
immune responses. Whereas this function of checkpoint in-
hibitory molecules is beneficial during resolution of infec-
tion, or in the development of self tolerance to prevent
autoimmune conditions [10–12], ligation of checkpoint in-
hibitory molecules can be a powerful and unwanted mech-
anism of immunosuppression in cancer [13–15]. Since the
successful introduction and FDA approved use of an anti-
body targeting checkpoint inhibitory molecule cytotoxic T
lymphocyte associated-4 (CTLA-4) (Ipilimumab; Yervoy®)
in patients with unresectable or metastatic melanoma in
2011 [16], this agent is now in use in over 40 countries. At-
tention has more recently focused on another checkpoint
inhibitory molecule programmed cell death-1 (PD-1) and
its ligand programmed cell death-1 ligand (PD-L1) [17–19].
Antibodies inhibiting PD-1 and PD-L1 have recently been
FDA approved for the treatment of cancer. For example,
the agent nivolumab (Opdivo®) is approved for unresectable
or metastatic melanoma, non-small cell lung cancer
(NSCLC), Hodgkin’s lymphoma and renal cell carcinoma.
Pembrolizumab (Keytruda®) is FDA approved for melan-
oma and NSCLC, and a blocking anti-PD-L1 antibody Ate-
zolizumab (Tecentriq®) is also FDA approved for
unresectable bladder cancer and for NSCLC. Blockade of
this pathway is particularly useful in patients as it is applic-
able to a wide range of cancers, and because it induces
anti-tumor immune responses capable of targeting mutated
proteins [20]. Importantly, treatment targeting PD-1 signal-
ing has fewer high grade toxicities than other immunother-
apies [13, 21].
Medical centers are currently utilizing these agents in
ongoing clinical trials for various cancers, including
ovarian cancer [7, 22, 23]. Initial reports of some trials
show promising objective response rates (ORR) for the
treatment of ovarian cancer with anti-PD-1 antibody
nivolumab (ORR of 15%, n = 20 patients), and pembroli-
zumab (ORR 11.5%, n = 49), or an anti-PD-L1 antibody
avelumab (ORR 10%, n = 124) [3, 24]. Those responding
often had durable responses, suggesting that if we could
identify the subgroup that might typically respond, we
could advance the therapeutic options in this subgroup
of ovarian cancer patients.
PD-1 is primarily expressed on CD4+ and CD8+ T cells
and is associated with T cell exhaustion [11, 12, 14]. PD-
L1 is expressed on many cell types including tumor cells
and macrophages, including those with an immunosup-
pressive phenotype [12, 25, 26]. Ligation of PD-L1 on
tumor cells with PD-1 on T cells, for example, abrogates T
cell proliferation, diminishes T cell activation and leads to
a predominance of a T helper 2 (Th2) cytokine tumor
microenvironment, with a pro-tumor propensity. Anti-
body blocking of PD-1 or PD-L1 restores T cell prolifera-
tive and cytotoxic functions, and induces a T-helper 1
(Th1) phenotype, thereby re-invigorating T cells, with
resulting potent anti-tumor capacity [14, 27, 28].
The immune mechanisms of disease improvement with
administration of checkpoint inhibitory molecules are not
well understood. Clinically, there is also ongoing debate
over which patients will benefit from this therapy, whether
patients who respond initially will continue to show
complete responses (CR) or partial responses (PR), and
whether patients’ tumors need to express PD-1 and/ or
PD-L1 in abundance, to predict beneficial responses to
checkpoint inhibitory molecule blocking therapy targeting
these molecules. At the present time, there are more ques-
tions than answers.
As a study of the immune microenvironment of ovarian
cancer patient tumors offers insight into the baseline im-
mune landscape associated with patient survival and tumor
pathology, and implicates broader scope for targeting these
molecules in combination studies with conventional therapy
and with other novel therapies, we undertook these present
investigations. We primarily selected advanced disease ovar-
ian cancer patients for study, since this group typically have
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poor outcome with standard therapy, and our future goal in
translational medicine is to address the need for novel alter-
native treatment options in this patient sector. We evaluated
the expression and localization of PD-1 and PD-L1 in a co-
hort of ovarian cancer formalin fixed paraffin embedded
(FFPE) tumor sections, and investigated whether the relative
expression levels of these molecules can be relevant patient
prognostic indicators. We also studied the impact of tumor
infiltrating lymphocytes (TILS) along with these checkpoint
molecules, on patient status including tumor grade, disease
stage and survival post diagnosis.
Methods
Patients
Patients underwent surgery between 2003 and 2006 at
Loyola University Medical Center (LUMC) for ovarian and
other gynecologic associated cancers. Tissues were embed-
ded in paraffin blocks for patient diagnosis to characterize
stage and grade of cancer in tissue sections, and blocks
were stored in the Department of Pathology, LUMC. After
receiving approval by the Institutional Review Board (IRB)
for the Protection of Human Subjects, we selected a cohort
of 55 patients for study, most of whom were diagnosed with
advanced disease ovarian cancer (Table 1). Patient histories
in the LUMC medical records were evaluated by two inves-
tigators and data collected for parameters including: age,
date of birth, date of diagnosis, pre-treatment status before
surgery, cancer stage, tumor grade, date of last encounter,
and whether the patient was alive or deceased. Dates of
death were retrieved from the patients’ medical records
when this date was available, or found by a search on a
website such as http://www.dobsearch.com/death-records/.
Antigen revealing
Formalin fixed paraffin embedded (FFPE) tissue sections
(4 μm) were adhered to glass slides using tissue from a
single patient on each slide for detection of PD-L1, PD-1,
CD3 and CD8 by immunohistochemistry (IHC). For stain-
ing of FoxP3 on T cells, patient tissue arrays were con-
structed from the paraffin embedded blocks and adhered
on a total of 2 glass slides with a core of tissue from each of
27 or 28 patients, as well as control tissues. Positive control
thymus tissue highly expressed the molecules/ markers
under study. Negative control tissue was sections of benign
ovarian disease such as polycystic ovarian disease. Sections
on slides were de-paraffinized in xylene and then rehy-
drated in a series of decreasing concentrations of alcohols.
Antigen retrieval for PD-L1 and PD-1 was performed by
boiling slides in a pressure cooker for 5 min in Universal
HIER retrieval agent (ab 208,572, Abcam, Cambridge, MA)
at a 1X concentration. Sections were washed in 0.1% tween
in Dulbecco’s phosphate buffered saline (DPBS; 1X, Lonza,
Walkersville, MD) and then blocked in 0.4% hydrogen per-
oxide in DPBS, followed by blocking in 10% goat serum
(S1000, Vector Laboratories, Burlingame, CA) for 1 h.
Antigen retrieval for FoxP3, CD3 and CD8 was performed
by boiling sections in a pressure cooker for 5 min in Reveal
Decloaker (RV1000G1, Biocare Medical, Concord, CA). After
washing in DPBS, sections were blocked in 0.4% hydrogen
peroxide in DPBS for 20 min, 10% goat serum or 10% horse
serum (S1000 or S2000 respectively, Vector Laboratories) for
20 min, and then in Avidin/ Biotin blocking reagents (SP
2001, Vector Laboratories) to further reduce non-specific
staining of primary antibody (FoxP3, CD3, or CD8).
Identification and assessment of antigens in patient
sections
Tissue sections were incubated overnight in 5% blocking
serum with or without primary antibody at a pre-determined
and optimized dilution. PD-1 (ab137132, Abcam) and PD-
L1 (ab205921, Abcam) were used at 1:500 dilution for IHC
staining. The next day sections were washed in 0.1% tween
in DPBS, and an amplifier polymer detection system specific
Table 1 Categories of patient tumors
Stagea Tumor type Histological subtype No. of patients
Low (I/ II) All
Ovarian
papillary mucinous cystadenocarcinoma
mixed adenocarcinoma, serous and endometroid
papillary serous adenocarcinoma
papillary serous carcinoma
serous carcinoma
1
1
2
4
1
High (III/ IV) Ovarian
Ovarian
Ovarian
Fallopian tube
Peritoneum
Peritoneum
Endometrium
Endometrium
Omentum
poorly differentiated serous carcinoma
papillary serous carcinoma
papillary serous adenocarcinoma
papillary serous carcinoma
papillary serous carcinoma
papillary serous adenocarcinoma
papillary serous carcinoma
serous carcinoma
papillary serous carcinoma
1
24
10
1
4
1
1
1
2
Total 55
aTumor stage reflects the International Federation of Gynecology and Obstetrics (FIGO) classification
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for rabbit anti-human primary antibodies (ab 20,901, Rabbit
specific IHC polymer detection kit; HRP/ DAB) added ac-
cording to the manufacturers’ guidance.Tissue was also
stained overnight with primary antibodies for FoxP3 (236A/
E7; ab 20,034, 1:1600 dilution, Abcam), CD8 (C8/144B; 1:
100 dilution, Cell Marque, Rocklin, CA 1:1000 dilution) and
CD3 (F7.2.38; 1:1000 dilution, Dako, Glostrup, Denmark).
Sections were washed in DPBS and a biotinylated secondary
antibody for peroxidase (PK 6102, Vector Laboratories)
added for 30 min, followed by an avidin-biotin peroxidase
complex and enzyme reagent (ABC, Vector laboratories). All
sections were washed in DPBS and developed in Vector
NovaRED (SK4800) or diaminobenzidine (DAB; SK4100,
Vector Laboratories). Sections were counterstained in
hematoxylin and rehydrated in xylene, followed by alcohol,
then mounted in Vectamount H-5000 (Vector Laboratories).
Tumor sections were examined by pathologists SM and
MA to investigate the frequency of occurrence of markers,
the degree of staining intensity and location of tumor cells or
lymphocytes expressing each molecule. A customized scor-
ing system was developed by the abovementioned patholo-
gists to obtain a numerical score to represent the average
frequency of antigens as visualized over 7–10 high power
fields (hpf) of IHC stained tissue sections (Table 2), where
“0” was the lack of expression, and “4” represented the high-
est frequency of expression of molecules in sections. In
addition to the scoring pattern shown in Table 2, in statistical
analysis, combined PD-1 was assigned as a mathematical
score which was derived by adding the observed pathology
scores (0–2) for T-PD-1 and S-PD-1 in each patient section.
In some statistical analysis PD-1 and PD-L1 expression
was classified as low (score of 1) or high frequency (score
of 2–4) to decipher correlations between the levels of ex-
pression of these molecules and parameters studied.
Statistical analysis
Patient O/S was displayed visually in Kaplan Meier plots
and significance of differences by strata were determined
with Log Rank tests. The frequency of occurrence of each
marker was graded on a scale from 0 to 4 (Table 2), and
Cochran Armitage tests used to determine the statistical
significance of trends by patient characteristics including
age, cancer stage and tumor grade. Associations between
the presence of PD-1, PD-L1, CD3, CD8 and FoxP3 posi-
tive cells with patient age at the time of diagnosis, cancer
stage, or tumor grade were determined with chi-square or
Fisher’s exact tests as appropriate. Hazard ratios for overall
survival (O/S) were determined from univariable Cox pro-
portional hazard regression models for each patient charac-
teristic and each marker. Analyses were performed using
SAS 9.4 (SAS Institute, Cary, NC).
Results
Patient characteristics
The cohort consisted of 55 patients as follows: ovarian (45
patients), fallopian tube (1 patient), peritoneum (5 pa-
tients), endometrium (2 patients) and omentum (2 pa-
tients) cancer tissue blocks. Patients were diagnosed as
stage I or stage II (stage 1 or 2, low/ early stage; 9 patients)
and stage III or IV (stage 3 or 4, high stage or advanced;
46 patients) disease (Table 1). One patient did not have
known cancer grade, and of the remaining, about three
quarters of patients had tumor grade 3 (n = 41, 75.9%).The
mean age of patients at the time of diagnosis was 61 years
(standard deviation = 12), with a range of 26 to 85 years.
At the time of last follow up, 6 patients were alive, 9 pa-
tients were lost to follow up (3 of whom were deceased at
an unknown date), and 40 other patients had recorded
dates of death, 38 of whom had died as a cause of ovarian
cancer. The median length of survival time for all patients
was 3.10 years (95% confidence interval (CI): 2.24–5.19).
Localization of checkpoint inhibitory molecules in ovarian
cancer tissue
We studied the distribution of PD-1 and PD-L1 in ovarian
cancer tissue sections by IHC staining. Sections were visu-
alized and staining evaluated by methods as outlined in
Table 2. Results showed that PD-1 in ovarian cancer tissue
was localized primarily to cell membranes. PD-1 stained
cells appeared to be primarily tumor infiltrating lympho-
cytes (TILs), with varying degrees of intensity of staining
and frequency of occurrence of these cells. Additionally,
this staining was strikingly evident in two separate com-
partments of the tumor microenvironment, thus we scored
this stain in two different categories. Intraepithelial TILs
completely enclosed by tumor epithelial cells and positive
for PD-1 were designated as tumor PD-1 cells (T-PD-1).
These cells were either clustered (Fig. 1a), or scattered in a
less dense pattern in the tumor epithelium (Fig. 1b). Cells
which stained positive for PD-1 in the stromal compart-
ment were termed stromal PD-1 (S-PD-1). In the stroma,
there were aggregates of cells staining positive for PD-1
Table 2 Pathological interpretation of IHC stained tissue
Marker Scoring criteria based on cells/ high power fieldsa
T-PD-1 0 = < 1; 1 = 1–10, 2= > 10–50 and 3= > 50
S-PD-1 0 = < 1, 1 = 1–25; 2= > 25–50 and 3= > 50
PD-L1 0 = < 1, 1= > 1–5, 2= > 5–10 and 3= > 10
CD3 0 = < 5, 1 = 5–15, 2= > 15–25, 3= > 25–40 and 4= > 40
CD8 0 = < 1, 1 = 1–25, 2= > 25–50 and 3= > 50
FoxP3 0 = < 1, 1 = 1–5, 2= > 5–15, 3= > 15–25 and 4= > 25 cells/ hpf
aBased on the known frequency of each marker in various cancer tissues, each
stained section was observed over 7–10 hpf and given an average numerical
value to represent the scoring frequency based on the categorization in Table
2. PD-1 was assigned 2 different scores to reflect the observed localization of
this molecule in tumor tissue. The percentage of PD-1 stained TILs completely
enclosed by tumor epithelial cells was termed tumor-PD-1 (T-PD-1). PD-1
stained lymphocytes in the stromal compartment were classified as
stromal-PD-1 (S-PD-1)
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(Fig. 1c), or regions of fewer cells staining for this molecule
(Fig. 1d). Table 3 shows a summary of scores for each PD-1
classification as well as the frequency of PD-1 observations
in tissue in the cohort of 55 patients studied. A total of 48
(87%) patients expressed PD-1 on cells, whilst 40 (73%) pa-
tients expressed PD-1 in both the epithelial (T-PD-1) and
stromal (S-PD-1) compartments (data not shown).
In tissue sections, PD-L1 was localized to the cell mem-
brane. In lesions of some patients there were solid tumor ag-
gregates with diffuse membranous staining of these cells for
this marker (Fig. 2a). PD-L1 was also identified in scattered
tumor cells with focal strong membranous staining (Fig. 2b).
Additionally, in some sections PD-L1 staining was observed
in cells with the morphology of immune cells (not shown).
Staining for this marker was positive in approximately one-
third (18 of 55, 33%) of patients with ovarian cancer.
Variable expression of tumor infiltrating lymphocytes in
ovarian cancer
Immunocompetent TILS and FoxP3 T regulatory cells, are
strategically located in ovarian cancer tissue. We sought to
determine whether the levels of CD3, CD8 and/ or FoxP3 T
cells in the tumors of patients would alter the potential role
of checkpoint inhibitory molecules as predictors of disease
pathology or of outcome. In FFPE tissue sections, of all T
cells, CD3 positive T cells were found in highest frequency, as
expected (Table 3), sometimes staining intensely. Some pa-
tients had an abundance of these cells, while other cases
showed a scattered arrangement (Fig. 3a and b respectively).
Staining for CD8 T cells was widely observed in patient sec-
tions as membranous reactivity, either with a dense distribu-
tion, or with lower frequency (Fig. 3c and d respectively).
Fig. 1 Distinct IHC staining patterns of PD-1 positive cells in the
stroma and epithelium of tissue. In ovarian cancer tissue sections,
tumor infiltrating lymphocytes (TILS) exhibiting strong membranous
and cytoplasmic staining for PD-1 are apparent as clusters (a) or single
scattered cells (b). TILS are also seen in aggregates (c) and as single
cells (d) in the reactive stroma associated with tumor
Table 3 Occurrence of checkpoint inhibitory molecules and
TILS in tumors
Molecules in
tumor sectionsa
Frequency Total patients
positive0 1 2 3 4
T-PD-1 10 35 10 0 0 45
S-PD-1 12 39 4 0 0 43
PD-L1 37 14 3 1 0 18
CD3 2 23 18 5 7 53
CD8 17 15 18 5 0 38
FoxP3 7 12 15 19 2 48
aTumor sections of 55 ovarian and related cancers were IHC stained for
molecules as indicated. Sections were visualized by microscopy and a
pathological score assigned from 0 to 4, based on the frequency of expression
of each molecule, where “0” indicates the absence and “4” the highest
frequency of expression
Fig. 2 Membranous staining of PD-L1 positive cells in ovarian tumors.
Diffuse membranous staining of almost all ovarian cancer cells (a)
versus focal strong membranous staining in a few scattered tumor cells
positive for PDL1 (b)
Fig. 3 High and low density of TILs in ovarian tumors. IHC staining
of T cell subsets in patients’ FFPE tissue sections. CD3 exhibiting
diffuse strong staining in clusters of tumor infiltrating lymphocytes
(a) versus focal staining in scattered TILs in less dense areas (b).
Distribution of CD8 T cells in clusters and as single cells is apparent
in c and d respectively
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FoxP3 staining of cells was revealed as strong nuclear reactiv-
ity, either in clustered foci in some patient sections (Fig. 4a),
or scattered in the tumor stroma in other cases (Fig. 4b).
FoxP3 positive cells were present in 48 of 55 patients.
Clinical parameters as predictors of patient prognosis
We examined trends between age of patients at the time
of diagnosis, tumor grade or tumor stage with overall sur-
vival. Significant parameters for these associations are rep-
resented in Kaplan Meier plots (Additional file 1: Figure
S1). We found that patients diagnosed with ovarian cancer
when over 60 years of age had a higher hazard of death
(HR: 2.63, 95% CI: 1.34–5.16) and were significantly more
likely to die as a cause of disease than patients diag-
nosed at a younger age (P = 0.005), (Additional file 2:
Table S1). Additionally, patients diagnosed with ad-
vanced disease (stage III or IV) had a higher hazard of
death (HR: 3.70, 95% CI: 1.28–10.76) and were signifi-
cantly more likely to die than patients diagnosed in
the early stages of the disease (P = 0.016). Tumor grade
had no significant association with patient survival
(Additional file 2: Table S1).
Similar analysis was performed to determine survival
estimates as a function of the expression of each marker.
It was found that while survival was similar in the first
few years of follow-up for those with or without PD-L1,
those with PD-L1 present in tissue sections appeared to
have a survival advantage with increased time after diag-
nosis, even though this trend was not statistically signifi-
cant (Additional file 3: Figure S2A). The presence of PD-
1 and of CD3 showed modest but insignificant trends to-
ward improved survival (Additional file 3: Figure S2 B
and C). CD8 or FoxP3 did not show a significant associ-
ation with survival, even though for high expression of
FoxP3 there was a trend towards decreased survival
(data not shown).
The presence of PD-L1 is positively associated with high
grade tumors
We undertook detailed analysis to determine how the pres-
ence of checkpoint inhibitor molecules, PD-1 or PD-L1
correlated with patient history. We did not find any signifi-
cant associations between the presence of PD-1, with pa-
tient age at the time of diagnosis, stage of cancer or tumor
grade (Table 4).
Only one patient with low tumor grade expressed PD-
L1, thus 17/18 (94%) patients who expressed PD-L1 in
their ovarian tumors had a tumor grade of 3. Thus PD-
L1 was expressed significantly more often in patients
with high grade tumor than in those with low grade
tumor (n = 54; 41.5% versus 7.7%, P = 0.040) (Table 4).
We did not observe any other significant associations
with the presence of any other molecules studied as sin-
gle predictors, with age at the time of diagnosis, stage of
disease or tumor pathology.
Further analysis of data showed that the presence of
CD3 or of FoxP3 infiltrating cells together with PD-L1
in patient tumors did not impact the significance of the
association of PD-L1 with high grade tumors (P = 0.040)
(Table 5). There was borderline significant association
between the presence of S-PD-1 cells together with
FoxP3 positive cells in tumors with high grade
(P = 0.075). The presence of TILs and of cells expressing
PD-1 or PD-L1 occurring together in ovarian tumors
had no impact on disease stage (Table 5), or on survival
(data not shown).
Low frequency of expression of PD-1 and of PD-L1
correlates with advanced ovarian cancer
We further investigated whether high or low frequency of
expression of PD-1 correlated with the stage or grade of
cancer. Based on our scoring pattern for the occurrence of
Fig. 4 Distribution of FoxP3 expressing T regulatory cells in ovarian
tumors. Intense nuclear staining of FoxP3 positive lymphocytes in a
focal arrangement (a). Other cases (b) showed nuclear staining of
fewer cells positive for this marker
Table 4 Patient history and presence of PD-1 and PD-L1
combined PD-1a PD-L1
No. Patients n (%) p-value n (%) P-value
Age at diagnosis
< 60 27 24 (88.9) 0.99 9 (33.3) 0.93
≥ 60 28 24 (85.7) 9 (32.1)
Stage of cancer
I-II 9 9 (100.0) 0.58 5 (55.6) 0.13
III-IV 46 39 (84.8) 13 (28.3)
Tumor grade
1–2 13 12 (92.3) 0.99 1 (7.7) 0.040
3 41 35 (85.4) 17 (41.5)
aThe presence of PD-1 in the tumor epithelial or stromal compartment
(combined PD-1), and PD-L1 was defined as the occurrence of these molecules
(scores 1, 2, 3, or 4) in tissue sections. Tumor grade was unknown for one
patient. Significant P-values are indicated in italics
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PD-1 in the tumor epithelium (T-PD-1) or in the stroma
(S-PD-1), we initially analyzed observations in these com-
partments separately. As expected, the frequency of PD-1
expressing cells in tumor tissue was in general not as high
as those expressing CD3 or CD8 (Table 3). A higher per-
centage of patients with early stage cancer were more
likely to have a higher frequency of expression (pathology
score of 2) of T-PD-1 than in patients with advanced
disease, but this difference was not significant (P = 0.13,
data not shown). In the case of S-PD-1, a higher percent-
age of patients with early stage cancer had higher levels
(frequency score of 2, 22%) of S-PD-1 than for advanced
disease patients (frequency score of 2, 2%) (P = 0.033)
(Additional file 4: Table S2).
A significantly higher percentage (33%) of early stage
patients had a higher frequency (score 3 and 4) of com-
bined PD-1 (PD-1 in the tumor epithelium and/or stroma)
than those with advanced disease (17%) (P = 0.028,
Table 6). Thus, a high density of PD-1 was significantly as-
sociated with early stage disease diagnosis, and a low PD-1
density was associated with advanced disease.
PD-L1 was expressed in 33% of the patient cohort. Scor-
ing for PD-L1 was performed by scoring regions of intense
or moderate staining for PD-L1 in either stromal or tumor
epithelial compartment, and an average of cells stained over
7 hpfs taken into account. Most patients (5/9; 56%) with
early stage disease expressed PD-L1. A lower percentage of
patients with advanced disease expressed PD-L1 (13/46;
28%) (Table 7). Most patients (11/13; 85%) with advanced
disease who expressed PD-L1, expressed this molecule in
tumors with a score of 1 (on a scale of 0–3). A higher per-
centage of patients with early stage disease (22%) expressed
high levels of PD-L1 (frequency score 2 or 3) in comparison
with patients with advanced disease (4.3%) (Table 7). There
were no significant trends in frequencies of CD3, CD8 or
FoxP3 with age at the time of diagnosis, stage of disease, or
tumor grade (data not shown).
Discussion
Ovarian cancer is usually diagnosed in the advanced meta-
static stages. Treatment of advanced stage disease with
conventional therapies is only sufficiently effective in a
limited number of patients, thus in about 80 % of these
patients there is disease progression or disease recurrence
and death, within five years of diagnosis. In many cancers,
Table 5 Association with immune markers, grade and stage
No. Patients n (%) with stage III-IV P-value n (%) with grade 3 P-value
Overall 55 46 (83.6) 41/54 (75.9)
aPresence with CD3
T-PD-1 + CD3 44 35 (79.5) 0.18 31 (72.1) 0.26
S-PD-1 + CD3 43 34 (79.1) 0.18 34 (81.0) 0.13
Combined PD-1 + CD3 47 38 (80.9) 0.33 34 (73.9) 0.66
PD-L1 + CD3 18 13 (72.2) 0.13 17 (94.4) 0.040
Presence with FoxP3
T-PD-1 + FoxP3 41 33 (80.5) 0.42 30 (75.0) 0.99
S-PD-1 + FoxP3 41 33 (80.5) 0.42 33 (82.5) 0.075
Combined PD-1 + FoxP3 44 36 (81.8) 0.67 33 (76.7) 0.99
PD-L1 + FoxP3 18 13 (72.2) 0.13 17 (94.4) 0.040
aEvaluation of the association of the presence of PD-1 or PD-L1 together with CD3 and FoxP3 T cells on advanced disease and on high grade tumors. Significant
P-values are indicated in italics
Table 6 Patient tumor and combined frequency of PD-1 expression
No. Patients 0 1 2 3 4 P-value
aCombined PD-1 Level, n (%)
Stage of cancer
I-II 9 0 (0.0) 0 (0.0) 6 (66.7) 1 (11.1) 2 (22.2) 0.028
III-IV 46 7 (15.2) 8 (17.4) 23 (50.0) 7 (15.2) 1 (2.2)
Tumor grade
1–2 13 1 (7.7) 4 (30.8) 7 (53.8) 0 (0.0) 1 (7.7) 0.54
3 41 6 (14.6) 4 (9.8) 21 (51.2) 8 (19.5) 2 (4.9)
aCombined PD-1 was derived by adding the observed pathology scores for tumor PD-1 (T-PD-1) and S-PD-1 in each patient tumor section. Significant
P-value in table is indicated in italics
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investigators are focusing on the development of novel
therapies as alternative and more robust options to exist-
ing therapies. Whereas conventional therapies primarily
focus on the destruction of tumor cells, many novel ther-
apies are designed to stimulate immune cells to elaborate
augmented anti-tumor immune responses. In this respect,
checkpoint immune inhibitory molecules have come full
circle over the last decade for cancer immunotherapy.
In a normal functioning immune system, T cell
activating and inhibitory receptors balance immune
tolerance, and the amplification of immune responses.
In the body, immune checkpoints are designed to reduce
autoimmune responses, or to attenuate immune re-
sponses which were elaborated after infections [10–12,
14, 27, 28]. In cancer, blocking of immune checkpoint
molecules with antibodies is a novel and promising ther-
apy, as it potentiates anti-tumor immune responses in
patients [9, 13, 15, 19].
The first of these checkpoint inhibitory molecules to
be targeted for blocking in therapy, and is now FDA ap-
proved for cancer therapy, is CTLA-4 [16, 17]. Therapy
design is based on the following principle. Binding of
costimulatory molecules CD80 or CD86 on antigen pre-
senting cells to CD28 on T cells delivers a positive costi-
mulatory signal contributing to T cell activation. On the
contrary, linkage of CD80 or CD86 to CTLA-4 (a mol-
ecule closely related to CD28) results in inhibition of im-
mune responses, and exhausted T cells, which are less
able to proliferate or to secrete T helper 1 (Th1) cyto-
kines [29] . Blocking of this inhibitory pathway with
anti-CTLA-4 antibodies, results in re-invigorated T cells
with greater proliferative function, and durable anti-
tumor potency [30, 31]. By similar rationale, there are
several other immune checkpoints in the immune
system, which are now being targeted in cancer clinical
trials. In the case of blocking PD-1 signaling, there are
currently about nine different antibodies in cancer
clinical trials targeting the PD-1/ PD-L1 pathway [3, 17].
This study was designed to better understand the ovar-
ian cancer tumor microenvironment (TME) with rela-
tion to the localization and frequency of PD-1, PD-L1
and TILS in the tumors of ovarian or related cancer pa-
tients, diagnosed with advanced disease. Firstly, results
showed that patients’ age was an independent prognostic
factor in survival, with patients over 60 years of age
more likely to die than those diagnosed when younger
than 60 years. This may be due to the fact that younger
patients can tolerate more aggressive surgery and
chemotherapy than older patients. Additionally, as ex-
pected, disease stage was also an independent prognostic
factor in outcome, such that patients diagnosed with ad-
vanced disease had a lower median survival than pa-
tients diagnosed with early stage disease. These findings
are in agreement with those of other investigators [32].
To shed light on the relevance of PD-1 and PD-L1 in
ovarian cancer outcome, we studied the abundance of these
molecules in the TME. PD-1 was compartmentalized in the
stroma and in the tumor epithelium, and this molecule was
expressed in 87% of tumors. PD-L1 was only present in the
tumors of 33% of patients. Patients who expressed PD-L1
had a trend towards survival, as did those expressing PD-1
or CD3, even though these trends were not significant. In
our cohort we did not find a significant association with
FoxP3 and survival. The presence of PD-L1 and FoxP3 to-
gether in high grade tumors showed the same level of asso-
ciation as the presence of PD-L1 alone. Some studies have
reported that FoxP3 positive cells in ovarian tumors is
negatively associated with outcome, however a meta-
analysis of 7 ovarian cancer studies with a total of 869 pa-
tients, did not find FoxP3 TILS in ovarian cancer to be a
significant prognostic indicator [33].
In cancer there are conflicting reports concerning the
expression patterns of PD-1 in patients’ tumors and the
association with survival, with either positive or a nega-
tive association [34–36]. One recent report found that
PD-1 positive TILS and /or PD-L1 positive tumor cells
had a positive association with survival of ovarian cancer
patients [37].
The expression of PD-L1 in tumors was shown to be
positively associated with survival in NSCLC [38] and in
ovarian cancer [37]. On the contrary, others report a
negative prognostic impact of PD-L1 expression in
Table 7 Patient tumor characteristics and frequency of PD-L1 expression
No. Patients 0 1 2 3 P-value
PD-L1 Level, n (%)
Stage of cancer
I-II 9 4 (44.4) 3 (33.3) 1 (11.1) 1 (11.1) 0.033
III-IV 46 33 (71.7) 11 (23.9) 2 (4.3) 0 (0.0)
Tumor grade
1–2 13 12 (92.3) 1 (7.7) 0 (0.0) 0 (0.0) 0.033
3 41 24 (58.5) 13 (31.7) 3 (7.3) 1 (2.4)
Significant P- values in table are indicated in italics
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ovarian cancer [39, 40] and breast cancer [41]. In a re-
view and meta-analysis of 17 studies using data of 2869
head and neck cancer (HNC) patients, authors found
that there was no significant association between the ex-
pression of PD-L1 on survival in HNC patients [42].
Additionally, similar analysis of reports with NSCLC pa-
tients also did not show a significant association with
PD-L1 expression and survival [43]. Taken together, this
indicates that the prognostic impact of PD-1/ PD-L1 ex-
pression in tumors is not yet established. Here, our stud-
ies did not find a significant association between survival
and PD-1 or PD-L1 expression in ovarian cancer.
Differences in reports of the expression of these mole-
cules and associations with survival may be attributed to
several reasons. Firstly, it is possible that there may be
different survival outcomes due to the site of cancer. For
example, Paulsen and colleagues [38] found that whereas
in a cohort of patients a high density of PD-1 and PD-L1
had a favorable impact on NSCLC, this association was
not present when these molecules were studied at meta-
static sites such as lymph nodes of the same patients.
This is highly likely because each cancer site has a differ-
ent immune landscape, and levels of soluble molecules
such as IFN-γ which is a strong regulator of PD-L1 ex-
pression [44, 45].
Secondly, differences in reports may be due to varia-
tions in staining protocols across individual laboratories.
Many investigators report difficulty in IHC staining for
PD-L1. In these present investigations, we initially used
tumor arrays to study the expression of PD-L1 and PD-1
in tumors. When optimizing our staining protocol, we
found that it was difficult to select cores which had a
good representation of tumor and stromal areas for ac-
curate visualization of the density of these molecules in
tissue arrays. Therefore, in this study we used whole
tumor sections for the identification of these molecules,
as is done for patient diagnosis. For molecules such as
PD-L1 especially, which is not widely expressed in
tumor tissues, reports in which IHC staining was per-
formed using tumor cores may give different findings
than reports from other laboratories in which staining
was performed using whole tissue sections.
Thirdly, the use of different primary antibody clones to
identify PD-1 or PD-L1 in tumor tissue in each laboratory,
may also lead to variability in staining of sections and in
interpretation. Finally, manual staining protocols in com-
parison with automated staining may further contribute to
variations in staining interpretation.
Finally, additional parameters which may alter the ex-
pression of these molecules in tumors, is the administra-
tion of treatments such as chemotherapy to patients
prior to surgery. However, at our center, for patients di-
agnosed with ovarian and related gynecologic cancer, the
primary treatment is most often surgery for removal of
tumors. Patients then undergo courses of standard ther-
apy such as chemotherapy. Consistent with this practice,
we found that a study of our patient cohort treatment
plans revealed that only 3 of 55 (5.5%) patients had
chemotherapy in the interval before surgery.
A low frequency of PD-1 in tumors was associated
with advanced disease. This association between low
PD-1 density and advanced disease was only significant
when measuring S-PD-1 or combined PD-1, whereas
low T-PD-1 density alone was not associated with ad-
vanced disease. Although beyond the scope of this study,
this finding raises the possibility that T-PD-1 and S-PD-
1 positive cells may perform unique immunosuppressive
roles in the ovarian TME.
PD-L1 expression was almost exclusively restricted to
high grade tumors, such that there was a positive and sig-
nificant association between PD-L1 and high grade tumors.
This finding may be of translational significance in selecting
patients for therapy blocking PD-1/ PD-L1 signaling, and
we suggest that patients with high grade tumors, with pre-
existing PD-L1 expression might be excellent candidates
for therapy blocking this pathway. In support of this idea, a
recent report shows that in an ongoing study of urothelial
bladder cancer patients, treatment with durvalumab
(MED14736; an anti-PD-L1 antibody) resulted in improved
outcome in PD-L1 tumor positive patients. In pre-
treatment tumor biopsies patients, 40 patients were PD-L1
positive and 21 patients negative for PD-L1. In 42 evaluable
patients, the ORR was 31.0% (95% CI, 17.6 to 47.1), the
ORR was 46.4% (95%CI, 27.5 to 66.1) in the PD-L1 positive
patient subgroup, and 0% (95% CI, 0.0 to 23.2) in patients
negative for PD-L1 [46].
We suggest that due to the conflicting reports concerning
the impact of PD-1 and PD-L1 on survival in cancer pa-
tients, a future larger study is needed investigating these
molecules in ovarian tissue, with standardized protocols
and defined cut off points for positive staining and scoring
criteria across centers, to minimize study variations. Even
so, the potency of patient responses to PD-1/ PD-L1 block-
ing antibody therapy may be influenced by the density of
other pre-existing or emerging checkpoint molecules in tu-
mors, including T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-
3) and V-domain Ig suppressor of T cell activation (VISTA).
Other parameters such as the presence of myeloid derived
suppressor cells, levels of Th2 cytokines (for example IL-
10) and of indoleamine 2,3-dioxygenase (IDO) can also
limit anti-cancer immune responses to therapy blocking
PD-1/ PD-L1 [19, 47, 48]. Furthermore, genetic alterations
within the tumor (including DNA rearrangements, muta-
tions, deletions and insertions) alter tumor mutational
loads, and it is reported that tumors with high mutational
loads have the greatest response to checkpoint inhibitory
blockade therapy [17, 49, 50].
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Finally, due to the multiplicity of factors regulating
ORR, we believe that antibody therapy targeting the PD-
1/ PD-L1 pathway in ovarian cancer will be of maximum
efficacy when used in combination with other treatment
regimens. Such treatments include standard therapy, im-
munotherapy blocking other checkpoint inhibitory mol-
ecules, dendritic cell vaccines, chimeric antigen receptor
(CAR) T cell therapy, or targeted therapy, all of which
can downregulate other immune suppressive mecha-
nisms in patients, concomitantly.
Conclusions
Treatments inhibiting PD-1 and PD-L1 are beneficial only
in some ovarian cancer patients. Our studies reveal that a
low density of PD-1 and of PD-L1 expressing cells in tumor
tissue are significantly associated with advanced disease,
and that PD-L1 is expressed significantly more in high
grade tumors than in low grade tumors. We conclude that
a subgroup of advanced disease ovarian cancer patients with
high grade tumors, bearing PD-L1, may be the best candi-
dates for immunotherapy targeting PD-1 and/ or PD-L1.
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